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DCs are key players in immune regulation and 
an important component of rational immuno-
therapeutic strategies in humans (Steinman, 
2008). In mouse, rat, and human species, DCs 
can  be  broadly  divided  into  two  groups   
(Villadangos and Schnorrer, 2007; Naik, 2008; 
Heath and Carbone, 2009; Merad and Manz, 
2009). Plasmacytoid DCs (pDCs) have variable 
antigen-presenting activity, but respond to vi-
ruses by producing IFN- via a Toll-like re-
ceptor (TLR)–dependent pathway (Gilliet et al., 
2008). In contrast, conventional DCs (cDCs) 
are known for their potent antigen-presenting 
activity and the ability to induce either T cell 
immunity or tolerance in response to self and 
foreign antigens. cDC have been extensively 
studied in mouse tissues, in particular the sec-
ondary lymphoid organs. In lymph nodes, cDCs 
encompass multiple subsets that are either de-
rived from blood-borne precursors or from   
afferent lymph-borne DCs emigrating from 
tissues. Mouse spleen lacks an afferent lymph 
supply, and therefore contains only blood-
derived cDCs. The latter express CD11c and are 
often divided into CD8+ and CD8 subsets, 
with CD8 subsets further subdivided on the 
basis of CD4 expression into CD4+ and CD4– 
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In mouse, a subset of dendritic cells (DCs) known as CD8+ DCs has emerged as an  
important player in the regulation of T cell responses and a promising target in vaccination 
strategies. However, translation into clinical protocols has been hampered by the failure to 
identify CD8+ DCs in humans. Here, we characterize a population of human DCs that 
expresses DNGR-1 (CLEC9A) and high levels of BDCA3 and resembles mouse CD8+ DCs in 
phenotype and function. We describe the presence of such cells in the spleens of humans 
and humanized mice and report on a protocol to generate them in vitro. Like mouse CD8+ 
DCs, human DNGR-1+ BDCA3hi DCs express Necl2, CD207, BATF3, IRF8, and TLR3, but  
not CD11b, IRF4, TLR7, or (unlike CD8+ DCs) TLR9. DNGR-1+ BDCA3hi DCs respond to poly 
I:C and agonists of TLR8, but not of TLR7, and produce interleukin (IL)-12 when given 
innate and T cell–derived signals. Notably, DNGR-1+ BDCA3+ DCs from in vitro cultures 
efficiently internalize material from dead cells and can cross-present exogenous antigens to 
CD8+ T cells upon treatment with poly I:C. The characterization of human DNGR-1+ 
BDCA3hi DCs and the ability to grow them in vitro opens the door for exploiting this subset 
in immunotherapy.
© 2010 Poulin et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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expressed by human blood BDCA3+ DCs (Galibert et al., 
2005). Thus, human blood BDCA3+ DCs might constitute 
a DC population equivalent to the mouse CD8+ DC sub-
set (Shortman and Heath, 2010). However, these cells have 
not been fully characterized and, in particular, it is unclear 
whether  they  constitute  a  homogeneous  population  and 
whether the rare BDCA3+ DCs circulating in blood repre-
sent DCs in human secondary lymphoid organs.
We and others have recently identified the C-type lectin, 
DNGR-1, also known as CLEC9A, as a novel marker for 
mouse CD8+ DCs and their CD8– CD24+ blood-borne 
precursors (Caminschi et al., 2008; Sancho et al., 2008). In-
terestingly, human DNGR-1 is highly restricted to BDCA3hi 
DCs among peripheral blood mononuclear cells (Caminschi 
et al., 2008; Huysamen et al., 2008; Sancho et al., 2008). 
We therefore hypothesized that the BDCA3 and DNGR-1 
markers together would be useful for identifying putative 
equivalents of mouse CD8+ DCs in human secondary lym-
phoid tissues and for purifying them for the purpose of char-
acterization. Here, we report that DNGR-1+ BDCA3+ 
double-positive DCs can be identified in primary human 
spleen, as well as in the spleens of mice reconstituted with 
human hematopoietic stem cells/hematopoietic progenitor 
cells (HSCs/HPCs). Additionally, we describe a protocol for 
growing populations of these cells in vitro from human cord 
blood  (CB)  HSCs/HPCs.  We  characterize  DNGR-1+ 
BDCA3+ DCs from all three sources and find that they have 
phenotypic and functional properties resembling those of 
mouse CD8+ DCs. We endorse the view that DNGR-1+ 
BDCA3+ DCs constitute a population of human DCs similar 
to the mouse CD8+ DC subset. The ability to generate these 
cells in humanized mice, and to grow them in vitro, offers tre-
mendous opportunity for studying their properties and for 
using them in immunotherapeutic approaches.
RESULTS
A discrete population of DNGR-1+ BDCA3hi DCs is present  
in human spleen
Mouse CD8+ DCs have been primarily isolated from spleen, 
and we asked if the latter organ in humans contains a DNGR-
1+ BDCA3+ DC subset. We screened samples from a bank of 
frozen cell suspensions that had been obtained less than 8 h 
post mortem by mechanical dissociation of healthy human 
spleens from cadaveric organ donors. Human DCs could be 
identified in all the samples by flow cytometry as HLA-DR+ 
cells lacking the lineage (Lin)-specific markers CD3, CD14, 
CD16, CD19, CD20, and CD56 (Fig. 1 A, top left, and 
Table S1). As in peripheral blood, DNGR-1 was found to be 
expressed exclusively by BDCA3hi DCs (population I; Fig. 1 A, 
top right). Like mouse CD8+ DCs, human spleen DNGR-
1+ BDCA3hi DCs were negative for CD11b and expressed 
slightly lower levels of CD11c than other DCs (Fig. 1 A and 
Fig. S1). Human spleen DNGR-1+ BDCA3hi DCs also did 
not express BDCA2, the pDC marker, or BDCA1 (CD1c), 
a more promiscuous marker also used to define human DC 
subtypes (Fig. 1 A and Fig. S1). The DNGR-1– population 
DCs (Villadangos and Schnorrer, 2007; Naik, 2008; Heath 
and Carbone, 2009; Merad and Manz, 2009). CD8+ DCs 
have attracted much attention and have been studied exten-
sively (Shortman and Heath, 2010). Compared with other 
DCs subsets, CD8+ DCs express much higher levels of cer-
tain gene products such as CD8, TLR3, CD36, CD103, 
and nectin-like 2 (Necl2) protein, but lower or undetectable 
levels of CD11b, TLR7, DCIR2 (also known as 33D1), RIG-I, 
MDA5, CD11b, and SIRP (Edwards et al., 2003; Galibert 
et al., 2005; Dudziak et al., 2007; Luber et al., 2010; Shortman 
and Heath, 2010). Certain proteins are expressed by CD8+ 
DCs and some DC subsets, but not by others. These include 
shared expression of DEC205 and Langerin (CD207) with 
Langerhans cells and a subset of dermal DCs, as well as shared 
expression of IRF8 with pDC (Inaba et al., 1995; Schiavoni 
et al., 2002; Takahara et al., 2002; Shortman and Heath, 
2010). Notably, CD8+ DCs, but not other DC subtypes 
have recently been shown to depend on the transcription fac-
tor Batf3 for their development, suggesting that they repre-
sent  an  ontogenetically  distinct  mouse  leukocyte  lineage 
(Hildner et al., 2008).
In addition to distinct gene expression profiles and on-
togeny, CD8+ DCs have several functional properties that 
distinguish them from other DC subtypes, albeit in a quanti-
tative rather than qualitative manner. These include a supe-
rior capacity to cross-present exogenous antigens on MHC 
class I, to ingest material from dead or dying cells, and to 
produce IL-12 in response to innate and T cell–derived 
stimuli (for review see Shortman and Heath, 2010). Because 
of these properties, CD8+ DCs have emerged as an attrac-
tive cellular target for vaccination strategies, in particular 
ones aimed at eliciting CTL responses against tumor or virus-
infected cells. In addition, CD8+ DCs can also induce 
conversion of antigen-specific T cells into regulatory T cells, 
suggesting that antigen delivery to CD8+ DCs could be 
used to dampen immune reactivity (Yamazaki et al., 2008). 
Unfortunately, the translation of mouse experiments into 
human studies and clinical protocols has been hampered by 
the fact that CD8+ DCs have not been identified in human 
(Naik, 2008). Nevertheless, distinct DC subsets can be pheno-
typically identified in human blood by HLA-DR expres-
sion, lack of antigens specific to other leukocyte lineages, 
and an additional set of markers known as blood DC anti-
gens (BDCAs; Dzionek et al., 2000). For example, BDCA2 
is a marker for circulating human pDCs, whereas BDCA3 
(also known as CD141 or thrombomodulin) marks a distinct 
small subset of blood DCs (Dzionek et al., 2000; MacDonald 
et al., 2002). Interestingly, a recent microarray analysis has 
indicated that BDCA3+ DCs from human peripheral blood 
have a transcriptional signature that resembles that of mouse 
spleen CD8+ DCs, despite the fact that they do not express 
CD8 (Robbins et al., 2008). In addition, blood BDCA3+ 
DCs  have  been  reported  to  be  expanded  in  volunteers 
treated with Flt3L (Galibert et al., 2005), a cytokine that also 
greatly  promotes  the  expansion  of  CD8+  DCs  in  mice 
(Maraskovsky et al., 1996). Finally, Necl2 is also selectively JEM VOL. 207, June 7, 2010 
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negative for CD11c, BDCA1, BDCA2, and CD11b (Fig. 1 A). 
In contrast, the BDCA3int population was heterogeneous 
and included CD11c BDCA2+ pDC that lacked CD11b 
and DNGR-1. Interestingly, BDCA3int cells also included 
CD11c+ DCs that variably expressed BDCA1, BDCA2, and 
CD11b (Fig. 1 A and Fig. S1). We sorted BDCA1– BDCA2– 
cells into BDCA3hi, BDCA3int, and BDCA3– populations. 
BDCA3hi DCs expressed mRNA for DNGR-1, Necl2, and 
IRF8 (Fig. 1 B), similar to mouse CD8+ DCs. BDCA3int 
and BDCA3– DCs expressed low or undetectable levels of 
DNGR-1, Necl2, and IRF8 mRNA (Fig. 1 B). We con-
clude that BDCA3 can be expressed by multiple human DC 
subsets, including pDC, but, at high levels of expression and 
especially in combination with DNGR-1, it marks a discrete 
population  of  human  spleen  DCs  that  resemble  mouse 
CD8+ DCs.
A discrete population of DNGR-1+ BDCA3hi DCs is found  
in spleens of humanized mice
Because of restricted access, paucity of DCs, and difficulty in 
recovering live cells from frozen samples, we were limited in 
the amount of analysis that we could carry out on primary 
human spleen (Table S1). Therefore, we assessed whether 
DNGR-1+ DCs could be identified in the spleens of mice 
reconstituted with human stem cells. Two xenotransplan-
tation  mouse  models  were  used  for  this  purpose:  NOD/
SCID/2m-null mice or NOD/SCID/c-null mice recon-
stituted with purified human CB HSCs/HPCs. In three in-
dependent successful xenotransplantation cohorts, HLA-DR+ 
Lin– human DCs were found in the spleens of all mice at 
8–12 wk after reconstitution, independent of the host mouse 
strain (Fig. 2 and not depicted). As in human spleen, distinct 
DC subsets could be defined on the basis of BDCA2, BDCA3, 
and DNGR-1 expression. They included DNGR-1– BDCA3– 
BDCA2– DCs, as well as DNGR-1– BDCA3int BDCA2+ 
cells that corresponded to pDCs. Notably, a separate popula-
tion of cells that were negative for BDCA2, but bright for 
BDCA3 and positive for DNGR-1, could also be identified 
(Fig. 2). These DNGR-1+ BDCA3hi cells were larger than 
BDCA2+ pDCs (Fig. 2) and resembled the ones in human 
spleen (see above). Thus, DNGR-1+ BDCA3hi DCs can be 
found in the spleens of humanized mice, in addition to those 
of humans.
Ex vivo generation of DNGR-1+ BDCA3+ DCs from human 
HSCs/HPCs
Although humanized mice proved a more useful source of 
DNGR-1+  BDCA3hi  DCs  than  primary  human  spleen, 
variation in chimerism and the low number of cells ob-
tained were limiting factors (unpublished data). Successful 
generation of DCs from hematopoietic stem cells has been 
achieved for Langerhans cells and dermal DC equivalents 
(Klechevsky et al., 2008). Therefore, we tried to generate 
DNGR-1+  DCs  in  vitro  from  human  CB  HSCs/HPCs 
(CB-derived DCs [CBDCs]). We set up cultures as a two step 
procedure: in the first step, HSCs/HPCs were amplified by 
included cells lacking BDCA3 (BDCA3, population III; 
Fig. 1 A, top right), as well as cells expressing moderate levels 
of the marker (BDCA3int; population II; Fig. 1 A, top right). 
BDCA3– DCs were relatively homogeneous and were mostly 
Figure 1.  DNGR-1+ BDCA3hi DCs are found in the spleens of  
humans. (A) Flow cytometry analysis of human spleen cell suspensions 
from cadaveric donors. Live HLA-DR+ Lin cells were gated as shown (top 
left) and analyzed for expression of BDCA3 versus DNGR-1 (top right). 
Three populations were defined (gate I: BDCA3hi, DNGR-1+; gate II: 
BDCA3int, DNGR-1; gate III: BDCA3, DNGR-1) and analyzed for the 
expression of CD11c versus BDCA1, BDCA2 or CD11b (bottom). Numbers 
indicate percentage of cells in each of the indicated gates or quadrants. 
Arrows show gating strategy. (B) Normalized expression of DNGR-1, 
Necl2, and IRF8 mRNA on sorted HLA-DR+ Lin BDCA2 BDCA1 DCs, 
from human spleen, expressing high (BDCA3hi), intermediate (BDCA3int), or 
low levels of BDCA3 (BDCA3). ND, not detectable. Data in A and B are 
representative of at least three cadaveric donors. Additional data analysis 
is shown in Fig. S1 and a summary of DC population frequency across 
three donors is presented in Table S1.1264 Characterization of human DNGR-1+ BDCA3+ DCs | Poulin et al.
consistent with the notion that SCF acts primarily to sus-
tain progenitor cells. In addition, DNGR-1+ BDCA3+ DCs 
could still be obtained when substituting TGF- for Flt3L in 
the  differentiation  cocktail  (unpublished  data).  DNGR-1+ 
BDCA3+ cells were not seen at 6 d of the differentiation 
culture in the presence of SCF, Flt3L, IL-3, and IL-6. The 
expanded cells were then aliquoted and tested in a variety of 
differentiation conditions for the ability to generate DNGR-1+ 
and/or BDCA3+ DCs. Flt3L was included in the differenti-
ation “cocktail” because BDCA3+ DCs are expanded in 
Flt3L-treated human subjects (Galibert et al., 2005), and 
Flt3L is essential for mouse DCs development (Merad and 
Manz, 2009). In addition, we used GM-CSF and IL-4, as 
these cytokines have been used to generate DCs in mouse 
and human. Finally, SCF was added to maintain HSC/HPC 
viability. Using HLA-DR and CD1a expression as a phe-
notypic  definition  of  in  vitro  HSC/HPC-derived  DCs 
(Klechevsky et al., 2008), we found that this culture sys-
tem generated 30–50% of Lin HLA-DR+ CD1a+ cells, 
which included a small percentage of the desired DNGR-1+ 
BDCA3+ double-positive subset (Fig. 3 A). Omission of 
any one of the four cytokines, SCF, Flt3L, GM-CSF, or 
IL-4, from the differentiation cocktail prevented the emer-
gence of DNGR-1+ BDCA3+ DCs by day 13 (Fig. S2 A), 
although small numbers of the cells could be recovered in 
the absence of SCF in longer cultures (e.g., 15 d; not depicted), 
Figure 2.  DNGR-1+ BDCA3hi DCs are found in the spleens of  
humanized mice. HLA-DR+ Lin live spleen cells from humanized mice 
(NOD/SCID/c) were analyzed as in Fig. 1 for the expression of BDCA3 
versus BDCA2 (top right), BDCA3 versus DNGR-1 (middle left), and BDCA2 
versus DNGR-1 (middle right). The scatter profile of BDCA3+ and BDCA2+ 
cells is also shown (bottom). Numbers indicate percentage of cells in each 
of the indicated gates or quadrants. Arrows show gating strategy. Data 
are representative of multiple mice from three independent cohorts of 
mice engrafted with human HSCs/HPCs.
Figure 3.  Phenotype of in vitro–generated DNGR-1+ BDCA3+ 
CBDCs. CBDCs were generated as described in the Materials and methods. 
Live cells were analyzed for the expression of BDCA3 versus DNGR-1 (A), 
CD1a versus DNGR-1 (B, left), and CD1a versus HLA-DR (B, middle). 
Gated CD1a+ HLA-DR+ cells were analyzed for the expression of BDCA3 
versus DNGR-1 (B, right). Numbers indicate percentage of cells in each 
of the indicated gates or quadrants. Arrows show gating strategy.  
(C) CBDCs were treated with or without poly I:C (10 µg/ml) overnight 
and subsequently sorted into live HLA-DR+ Lin DNGR-1+ cells. Cyto-
spins were prepared and morphology was assessed by hematoxylin and 
eosin staining. Bar, 5 µm. (D) Live DNGR-1+ DCs were analyzed for the 
expression (red) of CD11c, BDCA1, CD8, BDCA2, CD83, CD86, CD40, 
CD103, CD45RO, CD123, CCR7, EpCam, and CD11b. Isotype-matched 
control mAb staining is shown in the blue histograms. Data in A–D are 
representative of multiple BDC cultures with two independent pools of 
CB-derived HSCs/HPCs.JEM VOL. 207, June 7, 2010 
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As for the cells isolated from human 
spleen (Fig. 1 B), DNGR-1+ DCs 
purified from bulk CBDC cultures or 
from the spleens of humanized mice 
expressed  mRNA  for  DNGR-1, 
Necl2, and IRF8 (Fig. 4). IRF8 (and 
DAP12) was expressed at higher levels 
by BDCA2+ pDCs isolated in parallel 
from humanized mice (Fig. 4), consis-
tent with data in the mouse (Schiavoni 
et al., 2002). In contrast, the same pDCs 
did not express Necl2 or DNGR-1 
(Fig.  4).  Similar  to  mouse  CD8+ 
DCs, human DNGR-1+ DCs expressed CD207 and BATF3, 
but did not express mRNA for IRF4 or TLR7, which was 
restricted to pDCs (Fig. 4). Interestingly, TLR9 expression 
was also not expressed by DNGR-1+ DCs, but was expressed 
by pDCs (Fig. 4). This is different from the situation with 
mouse CD8+ DCs, which express TLR9. Finally, DNGR-1+ 
DCs, but not pDCs from humanized mice, expressed TLR3 
and TLR8 (Fig. 4). DNGR-1+ cells from CBDC cultures only 
expressed very low levels of the same TLRs (Fig. 4), possibly 
because of their immaturity. Consistent with the latter inter-
pretation, DNGR-1+ CBDCs up-regulated TLR3 and TLR8, 
but not TLR7, upon treatment with type I IFN, a known 
inducer of nucleic acid–sensing TLRs (unpublished data).
Human DNGR-1+ DCs resemble mouse CD8+ DCs  
in responsiveness to TLR agonists
Mouse CD8+ DCs express TLR3, but not TLR7, mRNA 
and respond to poly I:C, which is a TLR3 (and MDA5/
RIG-I) agonist, but not to imiquimod (R837), an agonist for 
TLR7 (Edwards et al., 2003). We purified DNGR-1+ DCs 
from CBDC cultures or from humanized mouse spleen and 
stimulated them with poly I:C or imiquimod. Independent 
of the source, DNGR-1+ DCs consistently responded to 
poly I:C, but not imiquimod, with production of TNF, 
IL-6, and other cytokines (Fig. 5 A and not depicted). A simi-
lar  response  pattern  was  seen  with  total  unfractionated 
CBDCs when measuring TNF production or surface HLA-DR 
up-regulation  as  a  marker  of  DNGR-1+  DCs  maturation 
(Fig. S3). In contrast, BDCA2+ pDCs from humanized mice 
responded to imiquimod, but not poly I:C, in the same 
experiments (Fig. 5 A). When trying various other TLR 
culture, but represented 3–6% of total live cells by 12 d, 
suggesting that they differentiate or expand as a late event. 
As  for  the  cells  in  primary  human  spleen,  CB-derived 
DNGR-1+ BDCA3+ DCs did not express CD14, CD11b, 
or BDCA2, but expressed CD11c (Fig. 3 D and Fig. S2 B). 
In contrast to primary human spleen DNGR-1+ BDCA3hi 
DCs, those from CBDCs expressed BDCA1 (Fig. 3 D), 
perhaps because of GM-CSF–driven induction of CD1a-c 
family members (Porcelli et al., 1992). CB-derived DNGR-
1+ BDCA3+ DCs expressed CD86 and CD45RO, but only 
low levels of CD123 (Fig. 3 D), as reported for blood 
BDCA3+ DCs (MacDonald et al., 2002). In contrast to 
mouse CD8+ DCs, DNGR-1+ BDCA3+ DCs did not ex-
press CD8 or CD103. They also did not express high 
levels of EpCam, indicating that they were not Langerhans 
cells (Bursch et al., 2007). Finally, CB-derived DNGR-1+ 
BDCA3+ DCs appeared to be immature, in that they did 
not express CD40, CD83, or CCR7 (Fig. 3 D). Consistent 
with immaturity, DNGR-1+ BDCA3+ DCs were not no-
ticeably dendritic until the CBDC cultures were treated 
with poly I:C (to promote DC maturation (Fig. 3 C). Thus, 
immature DNGR-1+ BDCA3+ DCs phenotypically similar 
to primary human spleen DNGR-1+ BDCA3hi DCs and   
to blood BDCA3+ DCs can be generated in vitro from 
human HSCs/HPCs.
Human DNGR-1+ DCs resemble mouse CD8+ DCs in gene 
expression pattern
To establish a possible equivalence between DNGR-1+ 
BDCA3+ human DCs and mouse CD8+ DCs, we analyzed 
the expression of selected gene products by quantitative PCR. 
Figure 4.  DNGR-1+ BDCA3+ DCs display 
a gene expression profile characteristic of 
mouse CD8+ DCs. Normalized expression of 
DNGR-1, Necl2, CD207, BATF3, IRF8, IRF4, 
TLR7, TLR9, DAP12, TLR8, and TLR3 mRNA in 
BDCA3+ DNGR-1+ DCs (DNGR-1+) purified 
either from CBDCs or from pooled spleens of 
two to five humanized mice (hu mice). Expres-
sion was compared with that of BDCA2+ pDCs 
purified from the same humanized mouse 
spleens. Data are representative of two inde-
pendent experiments. ND, not detectable.1266 Characterization of human DNGR-1+ BDCA3+ DCs | Poulin et al.
functional charac-
teristic  of  mouse 
CD8+  DCs.  In 
the  first  instance, 
we  used  unfrac-
tionated  CBDC 
cultures and com-
pared them to Mo-DCs. Unfortunately, the CBDC used for 
these experiments were only 50% HLA-A2+, as they were 
generated from HSCs/HPCs purified from pooled CB, whereas 
Mo-DCs  were  from  a  single  donor  and  homogenous  for 
HLA-A2 expression (unpublished data). This might be one 
reason why CBDCs were less efficient than Mo-DCs at 
presenting preprocessed antigenic peptides to HLA-A2– 
restricted T cell clones (Fig. S4). Nevertheless, CBDCs were 
at least as efficient as Mo-DCs at activating NY-ESO-1157-165–
specific T cells in response to intact recombinant NY-ESO-1 
protein, a clinically relevant antigen expressed by a broad range 
of tumor types (Chen et al., 2005; Fig. S4). The activation of 
the NY-ESO–specific T cell clone reflected true NY-ESO-1 
protein processing and cross-presentation, as it was not seen 
with CBDCs that were fixed in glutaraldehyde, even though 
the latter were still able to present the preprocessed deter-
minant (Fig. S4). Interestingly, this cross-presenting ability 
was only revealed upon treatment of DCs with poly I:C 
(Fig. S4), underscoring the importance of DC maturation in 
promoting antigen processing and presentation (Inaba et al., 
2000; Delamarre et al., 2003). Finally, we tested purified 
DNGR-1+ BDCA3+ CBDCs. We used a different model 
of cross-presentation, comprising a long Melan-A–derived 
peptide that requires processing for its (cross-)presentation 
to a specific HLA-A2–restricted T cell line (Faure et al., 
2009). As for the NY-ESO-1 protein, presentation of the 
long Melan-A peptide was only seen upon treatment of the 
DCs with poly I:C (Fig. 6 B). DNGR-1+ DCs were more 
efficient at cross-presenting the long peptide than Mo-DCs, 
even though the latter were more efficient at presenting the 
short peptide, representing the preprocessed determinant. 
We conclude that DNGR-1+ DCs have equal or superior 
cross-presentation ability to that of Mo-DCs.
agonists, we noticed that DNGR-1+ DCs also responded 
to resiquimod (R848) and poly U (Fig. 5 B). In the mouse, 
where there is lack of functional TLR8 expression, these 
compounds have been defined as TLR7 agonists (Diebold 
et al., 2004). However, in the human, they are reported to 
additionally stimulate TLR8 (Heil et al., 2004). The po-
tent response of DNGR-1+ BDCA3+ DCs to resiquimod 
and poly U, but not imiquimod, indicates that these cells 
can express functional TLR8.
Human DNGR-1+ DCs produce IL-12 in response to innate 
and T cell–derived stimuli
A hallmark of mouse CD8+ DCs is their ability to produce 
high levels of IL-12 in response to TLR agonists, especially in 
synergy with signals through the CD40, IL-4, GM-CSF, or 
IFN-  receptors  (Shortman  and  Heath,  2010).  DNGR-1+ 
DCs purified from CBDC cultures produced no IL-12 p70 
above background in response to stimulation with a cocktail of 
TLR agonists, even when these were given together with IL-4 
and IFN- (Fig. 5 C). However, the same cells produced IL-12 
p70 when antigen-specific T cells and antigen were added to 
the cultures (Fig. 5 C). Notably, this was also the case for pri-
mary DNGR-1+ DCs isolated directly from human spleen cell 
suspensions (Fig. 5 C). Thus, coordinate delivery of innate 
and T cell–derived stimuli reveals the ability of DNGR-1+ 
BDCA3+ DCs, including ones from human spleen, to produce 
bioactive IL-12.
Human DNGR-1+ DCs internalize dead cell material  
and cross-present exogenous proteins to CD8+ T cells
Another attribute of mouse CD8+ DCs is their superior ca-
pacity to internalize debris from dead or dying cells (Iyoda   
et al., 2002; Schulz and Reis e Sousa, 2002). DNGR-1+ DCs 
were able to take dead cell material and were superior in this 
regard to monocyte-derived DCs (Mo-DCs) generated using 
GM-CSF + IL-4 (Sallusto et al., 1995; Fig. 6 A). By microscopy, 
internalized dead cell material took the appearance of multiple 
small inclusions within a single DNGR-1+ DC (Fig. 6 A).   
Finally,  we  assessed  the  ability  of  DNGR-1+  BDCA3+ 
DCs to cross-present exogenous antigen to CD8+ T cells, a 
Figure 5.  DNGR-1+ BDCA3+ DCs respond 
to poly I:C and to TLR8, but not TLR7  
agonists. (A) Purified DNGR-1+ BDCA3+ DCs 
from CBDCs (DNGR-1+ CBDCs) or from hu-
manized mice (DNGR-1+ hu mice), or BDCA2+ 
pDCs from the same humanized mice 
(BDCA2+ hu mice), were cultured with poly I:C 
(10 µg/ml), imiquimod (10 µg/ml), or medium 
alone. After overnight incubation, culture 
supernatant was tested for TNF and IL-6  
content. (B) DNGR-1+ CBDCs as in (A) were 
cultured with resiquimod (10 µg/ml), poly U 
(10 µg/ml) or medium alone. Supernatant  
was tested for IL-6 after overnight culture.  
(C) DNGR-1+ BDCA3+ DCs purified from CBDCs 
(DNGR-1+ CBDCs) or human spleen (DNGR-1+ 
hu spleen) were cultured with a mix of TLR 
agonists and cytokines with or without anti-
gen-specific T cells and antigen, as described 
in the Materials and methods. Supernatant 
was tested for IL-12 p70 after overnight  
culture. Data in A–C are representative of at 
least two independent experiments with inde-
pendent sources of cells. ND, not detectable.JEM VOL. 207, June 7, 2010 
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data open the door for additional research to validate this 
concept and describe experimental systems in which this 
can be achieved.
We show that DNGR-1+ BDCA3hi DCs are present in 
normal human spleen, as well as in the spleens of humanized 
mice. Access to primary healthy human spleen samples was 
critical to establishing that the previously described BDCA3+ 
DCs in human blood are representative of DCs in lymphoid 
organs. Our ability to detect DNGR-1+ BDCA3hi DCs in 
human spleen cell suspensions is unlikely to be explained by 
blood contamination as DNGR-1+ BDCA3hi DCs represent 
0.05% of PBMC (Caminschi et al., 2008; Huysamen et al., 
2008; Sancho et al., 2008), yet make up 0.1% of total spleno-
cytes (Table S1). Thus, DNGR-1+ BDCA3hi human spleen 
DCs likely correspond to the rare Necl2+ cells previously 
found by immunofluorescence in human spleen sections 
(Galibert et al., 2005). Their low frequency among spleen 
cells is consistent with them being a rare cell type, although 
it may also relate to the method used for preparation of the 
cell suspension as, in mouse, mechanical dissociation of spleen 
without enzymatic digestion selects against CD8+ DC isola-
tion (Vremec et al., 1992). It will be interesting to extend our 
analysis to additional donors to determine if DNGR-1+ 
BDCA3hi human spleen DCs can show signs of in vivo acti-
vation related to bacterial infections or extent of trauma pre-
ceding death (McIlroy et al., 2001).
BDCA3+ DCs have been previously reported in human 
spleen (Velásquez-Lopera et al., 2008) and in the spleen and 
bone marrow of humanized mice (Cravens et al., 2005), but 
it is not clear whether they precisely correspond to the 
DNGR-1+ BDCA3hi population characterized here. Indeed, 
we find that although BDCA3 is expressed at the highest lev-
els by DNGR-1+ DCs, it is also expressed at lower levels 
by multiple DCs subtypes, including pDCs, in human and 
humanized mouse spleen. BDCA3 is also expressed by Lin+ 
non-DCs (MacDonald et al., 2002; unpublished data), and 
therefore caution must be exercised when using it as a marker. 
This is similar to the situation with DEC-205 in the mouse, 
which is expressed at highest level on CD8+ DCs and Langer-
hans cells, but is also expressed by other cell types (Witmer-Pack 
et al., 1995). Worryingly, we have noticed that use of dim 
fluorophores or inefficient flow cytometer calibration can result 
in contamination of the BDCA3hi population with BDCA3int 
cells and, during cell sorting, lead to false PCR results (un-
published data). For this reason, we would advocate the 
dual  use  of  DNGR-1  and  BDCA3  as  markers  to  define 
CD8+ DC equivalents in human. Notably, we and others have 
shown that antigen targeting to DNGR-1 is a useful strategy 
for inducing CTL responses and antibody responses in mice 
(Caminschi et al., 2008; Sancho et al., 2008), and can addi-
tionally be used to generate Th1 and Th17 or for converting 
antigen-specific CD4+ T cells into regulatory T cells (Joffre 
et al., 2010). Given that DNGR-1 appears to specifically 
mark the CD8+ DCs lineage across mouse and human spe-
cies, DNGR-1 targeting could also prove a useful method for 
antigen delivery to DCs in humans.
DISCUSSION
Analysis of leukocyte subsets in the mouse over the last 15 yr 
has highlighted the diversity of the DCs family and the no-
tion that distinct DCs types perform different immune func-
tions (Villadangos and Schnorrer, 2007; Naik, 2008; Heath 
and Carbone, 2009; Merad and Manz, 2009). Much atten-
tion has focused on the mouse CD8+ DCs subset and its 
role in immunity and tolerance, which could potentially be 
harnessed for immunotherapy of multiple diseases (Shortman 
and Heath, 2010). However, equivalent cells in humans have 
not been described. Here, we characterize DNGR-1+ BDCA3hi 
DCs as possible human equivalents of mouse CD8+ DCs. 
Like their putative murine counterparts, DNGR-1+ BDCA3hi 
DCs are large cells that express MHC class II, Necl2, Lan-
gerin, IRF8, BATF3, and TLR3, but not IRF4, CD11b, or 
TLR7. DNGR-1+ BDCA3hi further resemble mouse CD8+ 
DCs in their capacity to take up dead cell material, to re-
spond to poly I:C, but not TLR7 agonists, to produce IL-12 
p70 in response to innate and T cell–derived stimuli and in 
their cross-presenting properties and dendritic morphology 
that are revealed upon poly I:C stimulation. Although it   
remains to be formally proven that DNGR-1+ BDCA3hi 
DCs are the human equivalent of mouse CD8+ DCs, our 
Figure 6.  DNGR-1+ BDCA3+ DCs internalize dead cell debris and 
cross-present exogenous antigens. (A) CBDCs or Mo-DCs were incu-
bated with labeled dead melanoma cells at the indicated ratios, as  
described in the Materials and methods. Uptake of dead cell material by 
DNGR-1+ DCs or Mo-DCs was quantified by flow cytometry (left) and 
confirmed by confocal microscopy (right; blue shows dead cell material). 
Data are mean ± SEM of three biological replicates from one experiment 
representative of two independent experiments. Bar, 5 µm. (B) 104 purified 
BDCA3+ DNGR-1+ CBDCs or Mo-DCs, as indicated, were pulsed for 2–3 h 
with or without 1 µM MelanA/MART-1 long peptide as antigen source for 
cross-presentation or the same concentration of short peptide as a 
processing-independent control, in the presence or absence of poly I:C. 
Cells were subsequently washed twice and co-cultured with a MelanA-
specific CD8+ T cell clone at a 5:1 T:DCs ratio. IFN- accumulation in culture 
supernatants was assessed after 40 h. Data are the mean value of dupli-
cate wells ± range and are representative of two independent experiments.1268 Characterization of human DNGR-1+ BDCA3+ DCs | Poulin et al.
agonists suggests that RNA-based adjuvants would be useful   
alternatives for use in vaccination protocols aimed at target-
ing these cells in vivo. Interestingly, although TLR triggering 
was sufficient to promote secretion of IL-6 and TNF by 
DNGR-1+ BDCA3+ DCs, it was not sufficient to induce IL-12 
p70 production, even when given together with cytokines 
known to up-regulate the limiting IL-12 p35 subunit (Hochrein 
et al., 2000). In our experiments, production of IL-12 p70 by 
DNGR-1+ BDCA3+ DCs required additional feedback sig-
nals from T cells, reminiscent of the situation with mouse 
CD8+ DCs (Schulz et al., 2000). Notably, when normal-
ized for DC number, the levels of secreted IL-12 p70 repre-
sented  5  fg/ml/cell,  which  is  comparable  to  the  levels 
obtained from mouse CD8+ DCs or from human thymic 
DCs (Hochrein et al., 2000). Thus, DNGR-1+ BDCA3+ 
DCs could act as efficient producers of IL-12 in vivo upon 
appropriate stimulation.
Mouse CD8+ DCs have been reported to be restricted to 
the thymus and secondary lymphoid tissues. In contrast, BDCA3+ 
cells have also been found in human bronchioalveolar lavage 
fluid, lung, tonsils, dermis, decidua, and kidney (Demedts et al., 
2005; Lindstedt et al., 2005; Narbutt et al., 2006; Tsoumakidou 
et al., 2006; Ban et al., 2008; Fiore et al., 2008). However, 
Batf3-dependent CD11b– CD103+ Langerin+ DCs related to 
CD8+ DCs have recently been identified in mouse peripheral 
tissues (Bedoui et al., 2009; Ginhoux et al., 2009; Edelson et al., 
2010; Henri et al., 2010). Thus, there is a growing feeling that 
functional equivalents of CD8+ DCs in mouse and in other 
species may not necessarily be restricted to lymphoid tissues. In 
this regard, analysis of the distribution of DNGR-1+ BDCA3hi 
DCs in normal and pathological human specimens may yet 
prove very informative.
MATERIALS AND METHODS
Human tissue. Cell suspensions of human cadaveric spleen from healthy 
victims of traffic accidents (organ donors) were prepared <8 h post mortem by 
mechanical dissociation followed by Ficoll density centrifugation. Cells were 
frozen and stored in liquid nitrogen until used. The procedure was approved 
by the ULB-Erasme Ethics Committee of Hospital Erasme, Brussels, Belgium. 
CB was collected from mothers attending the Royal London Hospital, Lon-
don, UK, after informed consent through a protocol approved by the East 
London and City Research Ethics Committee. Mononuclear cells were ob-
tained by Ficoll density centrifugation and ammonium chloride red cell lysis. 
They were depleted for lineage marker positive cells using the StemSep system 
(STEMCELL Technologies Inc.) to generate Lin– HSCs/HPCs.
Humanized mice. All animal protocols were approved by the London 
Research Institute Ethics Committee and were performed under the author-
ity of a project license granted by the UK Home Office, in accordance with 
UK  governmental  regulations  (Animal  Scientific  Procedures  Act  1986). 
NOD/SCID/2microglobulin-null  mice  and  NOD/SCID/IL-2R-null 
mice were bred at Charles Rivers Laboratories, housed in microisolators, and 
fed sterile food and acidified water. Mice aged 8–12 wk were sublethally ir-
radiated (3.75 Gy) up to 24 h before i.v. injection of 50,000 Lin– human CB 
cells. Mice were analyzed 8–24 wk after reconstitution. Spleen cells were 
prepared by digestion with liberase and DNase, followed in some cases by an 
OptiPrep gradient to enrich for low-density cells (Sigma-Aldrich).
In  vitro–differentiated  DCs. Human Lin– CB cells differentiated into 
DCs using a two-step protocol. In the first step (amplification), Lin– cells 
In this paper, we additionally report on a set of culture 
conditions that allows the generation of DNGR-1+ BDCA3+ 
DCs from human HSCs/HPCs. The percentage of cells ob-
tained was low, suggesting that the culture system will benefit 
from additional optimization. Interestingly, the same cultures 
generated DNGR-1 BDCA3 DCs subsets, in addition to 
DNGR-1+ BDCA3+ DCs. Although it is tempting to draw 
an analogy with Flt3L cultures of mouse bone marrow, which 
can generate both CD8+-like and CD8– DCs after 8–10 d 
of culture in Flt3L (Naik et al., 2005), we found that DNGR-
1– BDCA3– DCs are not equivalent to CD8– DCs. In fact, 
DNGR-1– BDCA3– DCs are a mixed population that con-
tain, among others, precursors for DNGR-1+ BDCA3+ DCs 
(unpublished data). In this study, we ignored DNGR-1– DCs 
and focused exclusively on the DNGR-1+ BDCA3+ subset. 
Nevertheless, we believe that it may eventually be possible to 
use the same or a similar culture system to generate CD8– 
DCs equivalents, thereby permitting a direct comparison be-
tween the various subsets in humans. In the absence of a 
CD8– DCs comparator, we compared DNGR-1+ BDCA3+ 
to Mo-DCs. The latter are the most used cell type in studies 
of human DC biology, including studies of endocytic ability 
(Sallusto et al., 1995), and constitute the gold standard for 
cross-presentation studies in humans (Albert et al., 1998). We 
show that DNGR-1+ BDCA3+ DCs compare favorably to 
Mo-DCs in properties such as uptake of dead cells and cross-
presentation of exogenous antigens to CD8+ T cells. This is 
reminiscent of the situation with mouse CD8+ DCs, which 
are equal or superior to mouse bone marrow GM-CSF– 
derived DCs at cross-presenting exogenous antigens to CD8+ 
T cells. However, the APC functions of DNGR-1+ BDCA3+ 
DCs will need to be explored further, notably with regards to 
the ability to cross-present dead cell-associated antigens, as 
well as present antigens to MHC class II–restricted CD4+  
T cells. We have not yet been able to obtain sufficient numbers 
of cells to perform those experiments in a satisfactory man-
ner. Further work on validating the antigen-presenting prop-
erties of DNGR-1+ BDCA3+ DCs and the optimization of 
protocols for growing these cells in vitro may eventually   
allow for their use in antigen pulsing and adoptive transfer 
immunotherapy approaches, analogous to those currently   
using Mo-DCs.
Innate recognition pathways are key controllers of DCs 
function, and the repertoire of TLR expression by DC sub-
sets can act as a determinant of their properties. Like mouse 
CD8+ DCs, human DNGR-1+ BDCA3+ can express TLR3, 
but not TLR7, and can respond to poly I:C, but not imiqui-
mod. pDCs show a reciprocal pattern of response (Fig. 5 A), a 
fact that could be exploited in vaccination strategies designed 
to mobilize one and/or the other cell type. Interestingly, hu-
man DNGR-1+ BDCA3+ are not identical to mouse CD8+ 
DCs in regard to TLR9 expression, and it will be important 
to determine whether this might limit the effectiveness of 
CpG DNA oligonucleotides currently being tested as adju-
vants  in  humans  (Daubenberger,  2007).  Nevertheless,  the 
ability of DNGR-1+ BDCA3+ DCs to respond to TLR8 JEM VOL. 207, June 7, 2010 
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microscopy). Dead cells were added to 5 × 104 CBDCs or Mo-DCs at different 
ratios for 2 h at 4°C or 37°C. For confocal microscopy, cells were subse-
quently plated on fibronectin-coated coverslips for 15 min, fixed in 3.7% para-
formaldehyde/PBS for 10 min, permeabilized in 0.1% Triton X-100/PBS for 
3 min, blocked with 5% mouse serum, and stained for DNGR-1 using Alexa 
Fluor 546–coupled antibody. Coverslips were mounted in Fluoromount-G and 
imaged with a laser scanning confocal microscope (Axiovert 100M LSM 510; 
Carl Zeiss, Inc.) with a 63× Plan-Apochromat NA 1.4 oil objective. For flow 
cytometric analysis, cells were stained for DNGR-1 and BDCA3 and the per-
centage of CFSE+ DNGR-1+ BDCA3+ cells was calculated by subtracting 
the frequency of positive events at 4°C (binding) from the frequency at 37°C 
(binding + uptake).
Antigen presentation assays. NY-ESO-1157–165 peptide (Chen et al., 2000) 
or NY-ESO-1 full-length protein (provided by the Ludwig Institute of 
Cancer Research, New York, NY) and the MelanA/MART-1 short (ELA-
GIGILTV) or long (KGHGHSYTTAEEAAGIGILTVILGVL) peptides were 
used as antigen sources. Antigen presentation assays were performed as previ-
ously described (Salio et al., 2001; Faure et al., 2009) using HLA-A2–restricted 
NY-ESO-1– or MelanA-specific CD8+ T cells.
Online supplemental material. Table S1 show a summary of the analyses 
of human spleen DCs subsets in three different donors. Fig. S1 shows the 
phenotype of different DCs populations from human spleen defined on the 
basis of CD11c versus DNGR-1. Fig. S2 shows that DNGR-1+ BDCA3+ 
CB-derived DCs require Flt3L, GM-CSF, IL-4, and SCF to develop in vitro 
and do not express CD14. Fig. S3 demonstrates the differential response of 
bulk CBDC to poly I:C and imiquimod at the level of TNF production and 
HLA-DR up-regulation. Fig. S4 compares bulk CBDC and Mo-DCs for 
the ability to (cross-)present NY-ESO protein or peptide to antigen-specific 
T cells. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20092618/DC1.
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